髓源性抑制细胞在晚期胃肠道肿瘤化疗疗效评估中的临床意义

中国医药导刊 ›› 2021, Vol. 23 ›› Issue (3): 168-172.

髓源性抑制细胞在晚期胃肠道肿瘤化疗疗效评估中的临床意义

王雨雯，唐雨曼，吴冠冬，王振欣*

苏州大学附属第一医院肿瘤科，江苏苏州 215006

收稿日期:2021-01-11 修回日期:2021-02-08 出版日期:2021-03-28 发布日期:2021-03-28
基金资助:
江苏省研究生科研与实践创新计划（项目编号：SJCX20_1074；项目名称：MDSC与晚期肺癌化疗疗效相关性研究）

Significance of Myeloid-Derived Suppressor Cells in Evaluating the Efficacy of Chemotherapy for Advanced Gastrointestinal Cancer

WANG Yuwen， TANG Yuman， WU Guandong，WANG Zhenxin*

Department of Oncology， The First Affiliated Hospital of Soochow University， Jiangsu Suzhou 215006， China

Received:2021-01-11 Revised:2021-02-08 Online:2021-03-28 Published:2021-03-28

摘要/Abstract

摘要： 目的：检测晚期胃肠道肿瘤患者化疗前后外周血髓源性抑制细胞（MDSCs）的表达比例，分析其在化疗疗效评估中的临床意义。方法：应用流式细胞技术，检测33例晚期胃肠道肿瘤患者化疗前后外周血MDSCs表达比例，分析其变化趋势。结果：晚期胃肠道肿瘤患者外周血MDSCs的表达比例与患者性别、年龄、手术史、化疗史及癌种不相关（P＞0.05）。化疗无效组患者化疗后外周血MDSCs比例较化疗前增加，差异具有统计学意义（P＜0.05）；化疗控制组患者化疗后外周血MDSCs比例较化疗前减少，差异具有统计学意义（P＜0.05）。依据ROC曲线模型，化疗后外周血MDSCs的表达比例可作为患者疗效的判断指标（AUC=0.814，P＜0.05)。结论：晚期胃肠道肿瘤患者外周血MDSCs的表达比例可作为化疗疗效的重要监测指标。

关键词: font-size:medium, ">髓源性抑制细胞；晚期；胃肠道肿瘤；化疗；疗效

Abstract: Objective： To detect the proportion of myeloid-derived suppressor cells (MDSCs) in peripheral blood of patients with advanced gastrointestinal cancer before and after chemotherapy， and to analyze its clinical significance in the evaluation of chemotherapy effect. Methods： The proportion of MDSCs in peripheral blood of 33 patients with advanced gastrointestinal cancer were detected by flow cytometry before and after chemotherapy. Results： The proportion of MDSCs in peripheral blood of patients with advanced gastrointestinal cancer are not correlated with patients′ sex， age， operation history， chemotherapy history and cancer types (P>0.05). After chemotherapy， the proportion of MDSCs in peripheral blood of the patients in the chemotherapy-ineffective group is higher than that before chemotherapy，and the differences are statistically significant (P<0.05)， and the proportion of MDSCs in peripheral blood of the patients in the chemotherapy-controlled group is lower than that before chemotherapy， and the differences are statistically significant (P<0.05). Based on the ROC curve model， the proportion of MDSCs in peripheral blood after chemotherapy can be used as an indicator of chemotherapy efficacy（AUC=0.814， P<0.05). Conclusion： The proportion of MDSCs in peripheral blood of patients with advanced gastrointestinal cancer can be used as an important index to monitor the efficacy of chemotherapy.

Key words: font-size:medium, ">Myeloid-derived suppressor cells； Advanced； Gastrointestinal cancer；Chemotherapy； Efficacy

中图分类号:

王雨雯, 唐雨曼, 吴冠冬, 王振欣. 髓源性抑制细胞在晚期胃肠道肿瘤化疗疗效评估中的临床意义[J]. 中国医药导刊, 2021, 23(3): 168-172.

WANG Yuwen, TANG Yuman, WU Guandong, WANG Zhenxin. Significance of Myeloid-Derived Suppressor Cells in Evaluating the Efficacy of Chemotherapy for Advanced Gastrointestinal Cancer[J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2021, 23(3): 168-172.

参考文献

[1]Zheng ZX， Zheng RS， Zhang SW， et al.Colorectal cancer incidence and mortality in China， 2010[J]. Asian Pac J Cancer Prev，2014，15(19)：8455-8460
     [2]国家卫生和计划生育委员会《中国结直肠癌诊疗规范（2017年版）》专家组. 中国结直肠癌诊疗规范（2017年版）[J] .中华临床医师杂志（电子版），2018，12(1)： 3-23.
     [3]国家卫生健康委员会.胃癌诊疗规范(2018年版)[J]. 中华消化病与影像杂志(电子版)，2019，9(3)：118-144.
     [4]Draghiciu O， Lubbers J， Nijman HW， et al. Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacy[J]. Oncoimmunology，2015，4(1)：e954829.
     [5]Zhang B， Wang Z， Wu L， et al. Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma[J]. PLoS One， 2013，8(2)：e57114.
     [6]Schwartz LH， Litiere S， de Vries E， et al. RECIST 1.1-Update and clarification： From the RECIST committee[J]. Eur J Cancer，2016，62：132-137.
     [7]Fang JY， Shi YQ， Chen YX， et al. Chinese consensus on the prevention of colorectal cancer (2016， Shanghai)[J]. J Dig Dis， 2017，18(2)：63-83.
     [8]韩凌斐，郭晓青，胡家昌，等.宫颈癌患者外周血髓源性抑制细胞的比例及其临床意义[J]. 华中科技大学学报(医学版)，2015，44(1)：32-36.
     [9]彭蓉蓉，王胜军.肺癌患者外周血中髓源性抑制细胞的比例及其意义[J]. 江苏大学学报(医学版)，2019，29(1)：54-57.
     [10]张勇超，李潜，谢建国，等.直肠癌及癌前病变患者外周血髓源抑制细胞的表达及其临床意义[J]. 癌症进展，2018，16(4)：503-505+521.
     [11]王永仿，许联红，恽志华，等.结直肠癌患者外周血G-MDSC和M-MDSC水平与疗效的相关性分析[J]. 细胞与分子免疫学杂志，2018，34(6)：546-551.
     [12]Gabrilovich DI， Ostrand-Rosenberg S， Bronte V. Coordinated regulation of myeloid cells by tumours[J]. Nat Rev Immunol， 2012，12(4)：253-268.
     [13]Dolcetti L， Peranzoni E， Ugel S， et al. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF[J]. Eur J Immunol， 2010，40(1)：22-35.
     [14]Huang A， Zhang B， Wang B， et al. Increased CD14(+)HLA-DR (-/low) myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients[J]. Cancer Immunol Immunother， 2013，62(9)：1439-1451.
     [15]Koinis F， Vetsika EK， Aggouraki D， et al. Effect of first-line treatment on myeloid-derived suppressor cells′ subpopulations in the peripheral blood of patients with non-small cell lung cancer[J]. J Thorac Oncol， 2016，11(8)：1263-1272.
     [16]Kanterman J， Sade-Feldman M， Biton M， et al. Adverse immunoregulatory effects of 5FU and CPT11 chemotherapy on myeloid-derived suppressor cells and colorectal cancer outcomes[J]. Cancer Res，2014，74(21)：6022-6035.
     [17]广文.肿瘤标志物在消化道肿瘤性疾病诊疗中的临床价值[N]. 医药经济报，2017-07-03(011).

快速检索引用检索图表检索高级检索